Savara (SVRA) Short term Debt (2015 - 2022)

Savara (SVRA) reported Short term Debt of $12.5 million for Q1 2022, up 50.01% quarter-over-quarter from $8.3 million in Q4 2021.

Savara (SVRA) Short term Debt (2015 - 2022) Analysis & Trends

Savara (SVRA) has 7 years of Short term Debt data on file, last reported at $12.5 million in Q1 2022.

  • Short term Debt for Q1 2022 came in at $12.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was $12.5 million (changed N/A YoY), and the FY2021 annual result was $8.3 million, changed N/A from the prior year.
  • Short term Debt grew to $12.5 million in Q1 2022 per SVRA's latest filing, from $8.3 million in the prior quarter.
  • Over five years, Short term Debt peaked at $12.5 million in Q1 2022 and troughed at $1.9 million in Q2 2018.
  • A 4-year average of $5.4 million and a median of $4.0 million in 2018 frame the typical range for Short term Debt.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Savara 1.39 Bn 1.39 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2022 12.50 Mn
Dec 31, 2021 8.33 Mn
Sep 30, 2021 4.17 Mn
Dec 31, 2019 2.00 Mn
Sep 30, 2018 3.75 Mn
Jun 30, 2018 1.88 Mn
Mar 31, 2017 1.58 Mn
Dec 31, 2016 1.55 Mn
Sep 30, 2016 11.59 Mn
Jun 30, 2016 12.51 Mn
Mar 31, 2016 11.45 Mn
Dec 31, 2015 10.99 Mn
Sep 30, 2015 1.54 Mn